Whether AbbVie Korea’s ‘Rinvoq SR,’ which has been prescribed with reimbursement as an oral rheumatoid arthritis treatment since last year, will add an indication for atopic dermatitis, is gaining attention.

The industry believes it is highly possible, as the higher-dose formulation is soon to be approved in Korea, and the drug was approved for the atopic dermatitis indication in Europe in August last month.

According to industry sources, the Ministry of Food and Safety’s review for AbbVie Korea’s ‘Rinvoq SR 30mg’ is now complete, and the drug is pending approval.

Currently, only the 15mg dose is approved in Korea. Rinvoq SR 15mg is used to treat adults with moderat